1. Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma.
- Author
-
Zhang, Yichi, Ojalill, Marjaana, Boyer, Antonia, Chen, Xiao Lei, Tahon, Elise, Thivolle Lioux, Gaëtan, Xia, Marvin, Abbas, Maryam, Soylu, Halime Meryem, Flieder, Douglas B, Connolly, Denise C, Molinolo, Alfredo A, McHale, Michael T, Stupack, Dwayne G, and Schlaepfer, David D
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Cancer ,Ovarian Cancer ,Women's Health ,Rare Diseases ,4.2 Evaluation of markers and technologies ,Humans ,Female ,Cisplatin ,Ovarian Neoplasms ,Cell Line ,Tumor ,Focal Adhesion Kinase 1 ,Antineoplastic Agents ,Cell Nucleus ,Cell Survival ,MAP Kinase Signaling System ,Focal Adhesion Protein-Tyrosine Kinases - Abstract
SignificanceFAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type- and context-dependent.
- Published
- 2024